Significant role of Psf3 expression in non‐small‐cell lung cancer

Tane, Shinya; Sakai, Yasuhiro; Hokka, Daisuke; Okuma, Hitomi Sumiyoshi; Ogawa, Hiroyuki; Tanaka, Yugo; Uchino, Kenji; Nishio, Wataru; Yoshimura, Masahiro; Maniwa, Yoshimasa

doi:10.1111/cas.12770

Cited by 24 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diagnosis of adenocarcinoma is often based on identification of molecular markers of mutations, in particular EGFR, ERCC (DNA excision repair protein), RRM 1 (ribonucleoside-diphosphate reductase), KRAS (KRAS proto-oncogene), TS (thymidylate synthetase), and EML4-Alk (anaplastic lymphoma kinase receptor tyrosine kinase) [ 78 ]. Recently, protein PSF3 (DNA replication complex GINS) has become popular as a biomarker of adenocarcinoma [ 75 , 77 , 131 ]. PSF3 is a member of the heterotetrameric complex GINS (“go-ichi-ni-san” complex, from the first letters of the Japanese numbers 5-1-2-3) comprising SLD5 (Systemic RNA interference defective protein 5), PSF1 (GINS complex subunit 1), PSF2 (GINS complex subunit 2), and PSF3 (GINS complex subunit 3).…”

Section: Biomarkers Of Different Histological Lung Cancer Typesmentioning

confidence: 99%

Current and Prospective Protein Biomarkers of Lung Cancer

Zamay

Kolovskaya

et al. 2017

Cancers

133

View full text Add to dashboard Cite

Lung cancer is a malignant lung tumor with various histological variants that arise from different cell types, such as bronchial epithelium, bronchioles, alveoli, or bronchial mucous glands. The clinical course and treatment efficacy of lung cancer depends on the histological variant of the tumor. Therefore, accurate identification of the histological type of cancer and respective protein biomarkers is crucial for adequate therapy. Due to the great diversity in the molecular-biological features of lung cancer histological types, detection is impossible without knowledge of the nature and origin of malignant cells, which release certain protein biomarkers into the bloodstream. To date, different panels of biomarkers are used for screening. Unfortunately, a uniform serum biomarker composition capable of distinguishing lung cancer types is yet to be discovered. As such, histological analyses of tumor biopsies and immunohistochemistry are the most frequently used methods for establishing correct diagnoses. Here, we discuss the recent advances in conventional and prospective aptamer based strategies for biomarker discovery. Aptamers like artificial antibodies can serve as molecular recognition elements for isolation detection and search of novel tumor-associated markers. Here we will describe how these small synthetic single stranded oligonucleotides can be used for lung cancer biomarker discovery and utilized for accurate diagnosis and targeted therapy. Furthermore, we describe the most frequently used in-clinic and novel lung cancer biomarkers, which suggest to have the ability of differentiating between histological types of lung cancer and defining metastasis rate.

show abstract

Section: Biomarkers Of Different Histological Lung Cancer Typesmentioning

confidence: 99%

Current and Prospective Protein Biomarkers of Lung Cancer

Zamay

Kolovskaya

et al. 2017

Cancers

133

View full text Add to dashboard Cite

show abstract

“…Recently, several studies have shown that each GINS member is associated with malignant progression in several different tumor histotypes, i.e., PSF1 for breast cancer 3 , colon cancer 4 , and lung cancer 5 , PSF2 for cholangiocarcinoma 6 , and PSF3 for colon cancer 7 and non-small cell lung cancer 8 . Although we previously reported on the levels of expression of SLD5 in different cancer cell lines 7 , to the best of our knowledge there have been no reports thus far on its expression and malignant tumor progression.…”

mentioning

confidence: 99%

Regulation of SLD5 gene expression by miR-370 during acute growth of cancer cells

Yamane

Naito

Wakabayashi

et al. 2016

Sci Rep

View full text Add to dashboard Cite

SLD5 is a member of the GINS complex, essential for DNA replication in eukaryotes. It has been reported that SLD5 is involved in early embryogenesis in the mouse, and cell cycle progression and genome integrity in Drosophila. SLD5 may be involved in malignant tumor progression, but its relevance in human cancer has not been determined. Here, we found strong SLD5 expression in both human bladder cancer tissues from patients and cell lines. Knockdown of SLD5 using small interfering RNA resulted in reduction of cell growth both in vitro and an in vivo xenograft model. Moreover, we found that high levels of SLD5 in bladder cancer cells result from downregulation of microRNA (miR)-370 that otherwise suppresses its expression. High level expression of DNA-methyltransferase (DNMT) 1 and IL-6 were also observed in bladder cancer cells. Knockdown of IL-6 led to downregulation of DNMT1 and SLD5 expression, suggesting that IL-6-induced overexpression of DNMT1 suppresses miR-370, resulting in high SLD5 expression. Our findings could contribute to understanding tumorigenic processes and progression of human bladder cancer, whereby inhibition of SLD5 could represent a novel strategy to prevent tumor growth.

show abstract

“…Psf3 was upregulated in the pulmonary adenocarcinoma cell line A549 and lung squamous cell carcinoma cell line EBC 1, and knockdown of Psf3 delayed the S phase of the DNA in the cell lines. These indicated that Psf3 played a role in the DNA replication of lung cancer cells and was an essential factor in lung cancer proliferation …”

Section: Discussionmentioning

confidence: 96%

“…These indicated that Psf3 played a role in the DNA replication of lung cancer cells and was an essential factor in lung cancer proliferation. 17 Previous reports have demonstrated that UFT improved the prognosis of patients with active DNA synthesis in tumors. [18][19][20] We considered that the efficacy of UFT might be relatively high in malignant cells in which DNA replication is active.…”

Section: Discussionmentioning

confidence: 99%

Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundPartner of Sld five 3 (Psf3) is a member of the heterotetrameric complex that consists of SLD5, Psf1, Psf2, and Psf3. We have shown in previous studies that high Psf3 expression was a poor prognostic marker for pulmonary adenocarcinoma. Here, we statistically evaluated the relationship between clinicopathologic factors and Psf3 expression in stage I pulmonary adenocarcinoma.MethodsA total of 583 patients who had undergone complete resection of stage I pulmonary adenocarcinoma from January 2002 to December 2009 were included in the study. Tissue microarrays were performed, and the resected tumors were divided into groups according to Psf3 expression.ResultsOf 583 patients, high expression of Psf3 was observed in 211 (36.2%) and low expression of Psf3 observed in 372 (63.8%) patients. Among stage I patients, the five‐year survival rate was 76.7% in the Psf3 high expression group and 90.9% in the Psf3 low expression group (P < 0.0001). On multivariate analysis, Psf3 was found to be the independent prognostic factor. Among stage I patients in the Psf3 high expression group, a significantly greater five‐year survival rate was observed in patients who received postoperative chemotherapy with tegafur‐uracil than in those who underwent surgery alone (P < 0.0001). In contrast, among stage I patients in the Psf3 low expression group, no difference was found in the five‐year survival, regardless of the presence or absence of tegafur‐uracil (P = 0.873).ConclusionThe Psf3 expression was an independent prognostic factor and could be a biomarker of adjuvant tegafur‐uracil for stage I pulmonary adenocarcinoma.Key points Significant findings of the study: The Psf3 expression could be a biomarker of adjuvant tegafur‐uracil administration for stage I pulmonary adenocarcinoma. What this study adds: Appropriate patients of adjuvant chemotherapy for stage I pulmonary adenocarcinoma using Psf3 expression could be selected.

show abstract

Significant role of Psf3 expression in non‐small‐cell lung cancer

Cited by 24 publications

References 26 publications

Current and Prospective Protein Biomarkers of Lung Cancer

Current and Prospective Protein Biomarkers of Lung Cancer

Regulation of SLD5 gene expression by miR-370 during acute growth of cancer cells

Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma

Contact Info

Product

Resources

About